{
  "docId": "019dd923-5f69-752d-a9b7-cb9ca917cc95",
  "docSlug": "RKx0dsiKeHCYSDIkE7uF",
  "documentTitle": "Cyclica is already using AI to discover new medicines based on psychedelics. Here's the presentation the biotech startup used to raise a fresh $17 million.",
  "authorId": "Pitchdecks",
  "authorName": "Cyclica",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.78,
  "pageNumber": 6,
  "pageCount": 10,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "business_model",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a hub-and-spoke diagram to illustrate the business model flow.",
  "elementsJson": [
    "action_title",
    "paragraph",
    "flowchart"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5f69-752d-a9b7-cb9ca917cc95/6",
  "deckHref": "/decks/019dd923-5f69-752d-a9b7-cb9ca917cc95",
  "deckJsonHref": "/decks/019dd923-5f69-752d-a9b7-cb9ca917cc95.json",
  "deckAnchorHref": "/decks/019dd923-5f69-752d-a9b7-cb9ca917cc95#slide-6",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Our partnership models create a diversified portfolio of assets across multiple indications that will usher in a tidal wave of molecules into the clinic in the next 3 to 5 years.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd952-a28e-768f-b415-97a34d61063f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.9,
        "x": 0.05,
        "y": 0.35
      },
      "kind": "diagram",
      "text": "Cyclica hub-and-spoke business model diagram",
      "attrs": null,
      "subkind": "hub-spoke",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "007f12c8-3633-4115-9858-f4ca3171a662",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.22
      },
      "kind": "paragraph",
      "text": "Our partnership models create a diversified portfolio of assets across multiple indications that will usher in a tidal wave of molecules into the clinic in the next 3 to 5 years. These partnerships will also provide a robust pipeline directly to larger companies for clinical development.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4799e4c9-8eb9-4d0f-a92c-3214734b403b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "title",
      "text": "We believe that the future of pharma is in the hands of innovative biotech companies",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "032fe133-09fe-44a5-90c4-3cab97c6c8b3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.1
      },
      "kind": "title",
      "text": "Big pharma companies are increasingly looking to biotech companies for discovery opportunities.",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ec45ddc4-4fa6-42d9-92de-73fdf8395421",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "hub-spoke",
      "slug": null,
      "matchId": "a7dcfc50-910f-4d2c-bf89-05b600b59ef6",
      "evidence": "Central Cyclica node connecting external partners to large companies",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 6,
      "from": 6,
      "beatId": "8b8a2f71-f2eb-4ef4-b8d9-65c323806c16",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Business Model",
      "beatSlug": "sequoia-pitch-business-model",
      "evidence": "Slide 6 discusses Cyclica's business model and its adoption in the industry.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 9,
      "from": 3,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "6deaf774-516a-46da-9cd4-8fce54352f51",
      "evidence": "The document implies that traditional AI in drug discovery companies are limited, and Cyclica's platform offers a more comprehensive solution.",
      "position": 0,
      "objective": "What is the cost of not adopting a more holistic approach to drug discovery?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}